PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Exenatide - Diabetes Mellitus

PAD Profile : Exenatide - Diabetes Mellitus

Keywords :
GLP-1 with insulin; diabetes guidelines
Brand Names Include :
Bydureon

Traffic Light Status

Status 1 of 2.

Status :
Green (see narrative)
Important
Formulations :
  • Not Specified
Important Information :
Exenatide is not a preferred treatment option. The preferred GLP-1 for WEEKLY injection is dulaglutide. Prescribing may continue on existing patients.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Status 2 of 2.

Status :
N/A
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
07 February 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Not a preferred treatment option. See guidelines below and associated documentation for further information

Associated BNF Codes

06. Endocrine System
06.01.02. Antidiabetic drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More